Please assess the completion status of the following clinical trial:

Trial Title: Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's referred for radiofrequency ablation (RFA) or cryoablation for atrial fibrillation or atrial flutter (left atrial).~* Age ≥ 18 year~* Patients who are mentally and linguistically able to understand the aim of the trial, comply with the trial protocol, verbally acknowledge the risks, benefits, and alternatives in this trial.~Exclusion Criteria:~* Previous intolerance or allergy to heparin products.~* Current or prior administration of protamine products~* History of femoral access site complications including hematoma, AV fistula, pseudoaneurysm, aneurysm.~* Known lower extremity venous thrombosis.~* Coagulopathy or blood dyscrasias.~* Active malignancy.~* Thrombocytosis (platelet count \>600k/ul) or thrombocytopenia (platelet count \<100k/ul)~* Planned use of vascular closure device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of \<200s or return to pre-procedural baseline prior to sheath removal.
- Protamine (Type: ACTIVE_COMPARATOR): Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of \<200s or return to preprocedural baseline prior to removal of vascular sheaths.

Based on this trial design, predict the completion outcome and termination type (if applicable).